Clinical Research Directory
Browse clinical research sites, groups, and studies.
PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition
Sponsor: Taipei Medical University
Summary
The expected outcome of this study is that continuous 8-week supplementation with the PI-YSP-0111 prebiotic formulation will exert beneficial effects on gut microbiota modulation and liver health.
Official title: Evaluation of the Effects of the PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-04-08
Completion Date
2027-04-07
Last Updated
2026-06-01
Healthy Volunteers
Yes
Conditions
Interventions
PI-YSP-0111 formulation (High-dose)
6 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)
PI-YSP-0111 formulation (Low-dose)
4 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)
Placebo group(High-dose)
6 per day(Maltose powder, Aerosil, Magnesium Stearate)
Placebo group(Low-dose)
4 per day(Maltose powder, Aerosil, Magnesium Stearate)
Locations (2)
Taipei Medical University
Taipei, Taiwan, Taiwan
Taipei Municipal WanFang Hospital(Managed by Taipei Medical University)
Taipei, Taiwan, Taiwan